Recent news on Frova

Nothing Wrong With Endo  -  Apr 30, 2007
Motley FoolIn March, Endo announced the FDA was extending its review of the supplemental New Drug Application (sNDA) that was filed for migraine treatment Frova.

No Pain for Endo's Investors  -  Apr 30, 2007
Motley FoolIn other developments, Endo has submitted a supplemental New Drug Application to increase the label indications for migraine treatment Frova to include the

Endo Pharmaceuticals Reports First Quarter 2007 Financial Results  -  Apr 27, 2007
PharmaLive.com (press release),Frova(R). Net sales of Frova(R) were $12.1 million for the three months ended March 31, 2007, up 73% from $7.0 million in the same period a year ago.

Endo Pharmaceuticals, A different model  -  May 2, 2007
British Industry,Currently it has five major branded prescription products (used to treat and manage pain) on the market: Lidoderm, Percocet, Frova, Opana, and Opana ER.

Vernalis plc Announces Pricing and Reimbursement for Frova® in France  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),Following launch in France planned for later this month, Menarini will market Frova® in all of the major European pharmaceutical markets.

Endo and Vernalis Plc Announce Three-Month Extension of PDUFA Date ...  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),...“We look forward to working with the FDA to expand Frova®’s indication and bring this important new prophylactic treatment for menstrual migraine to market

UK Stocks Advance, Led by Alliance Boots, Standard Chartered  -  Apr 20, 2007
BloombergUS regulatory approval of Frova for the prevention of Menstrual Migraine, expected in August, ``will be important for sentiment.''

Alliance Boots, Persimmon, WPP: UK, Irish Equity Preview  -  Apr 19, 2007
Bloomberg...``FDA approval of Frova in the prevention of Menstrual Migraine,'' which is expected in August, ``will be important for sentiment.''

3 More Kings of Cash  -  27 Mar 2007
Motley Fool...steadily progressing pipeline, and a solid stable of branded products -- like Opana, Frova, and Percocet -- to keep its canons stuffed with cash.

FDA wants three more months to review Frova expansion  -  Mar 19, 2007
Pharma Times (subscription),Frova was approved by the FDA to treat acute migraine attacks in November 2001 and Vernalis recently announced that it has received pricing and

Endo, Vernalis Plc Drug Frova FDA Review Period To Be Extended ...  -  Mar 16, 2007
WebWire (press release),..."We look forward to working with the FDA to expand Frova(r)’s indication and bring this important new prophylactic treatment for menstrual migraine to

Endo: FDA Needs 3 More Months for Frova  -  Mar 16, 2007
Forbes,The companies hope to the get Frova approved for short-term prevention of menstrual migraine. The FDA is now expected to make a decision by Aug.

Endo's Frova delayed on new-use approval  -  Mar 16, 2007
United Press InternationalFrova was previously approved for the acute treatment in adults of migraine attacks with or without aura, or subjective symptoms at the onset of a migraine.

Vernalis plc Announces Pricing and Reimbursement for Frova in France  -  Mar 12, 2007
PharmaLive.com (press release),Frova(R) in France. Following launch in France planned for later this month, Menarini will market Frova(R) in all of the major European pharmaceutical

Vernalis plc Announces Pricing and Reimbursement for Frova in France  -  Mar 11, 2007
Primenewswire (press release),Following launch in France planned for later this month, Menarini will market Frova(r) in all of the major European pharmaceutical markets.

A Slowdown at Endo  -  Mar 20, 2007
Motley FoolFrova's PDUFA date, May 19, was the goal for when the FDA would give the marketing thumbs up or down for the drug. In this case the PDUFA date was extended

Vernalis upgraded to "hold"  -  Mar 22, 2007
newratings.comThe analyst expresses his concern regarding the prospects for Frova and Apokyn, the company’s two marketed drugs. The forthcoming significant news would be

FDA needs more time to review expanded use of Endo drug  -  Mar 17, 2007
Milwaukee Business Journal,Endo (NASDAQ:ENDP) of Chadds Ford, Pa., and its marketing partner Vernalis of Winnersh, England, are seeking to have Frova's label expanded to include its

High R&D costs lead to bigger losses at Vernalis  -  Mar 14, 2007
Pharma Times (subscription),Following a launch there, planned for later this month, Menarini will market Frova in all of the major European pharmaceutical markets.

FDA Informs To Endo Pharma And Vernalis About Additional 3 Months ...  -  Mar 16, 2007
Trading Markets,Frova was approved by the FDA on November 8, 2001 for the acute treatment of migraine attacks with or without aura (subjective symptoms at the onset of a

Endo drug needs more FDA review  -  Mar 17, 2007
Chester Daily Local Online,The marketing partners are seeking to have Frova’s label expanded to include its use for the short-term prevention of menstrual migraines.

Business in brief  -  Mar 17, 2007
The News Journal,The FDA is expected to complete its review of the companies' application for Frova by Aug. 19. The review was to have been completed by May 19.

USextends review of Endo-Vernalis drug to August  -  Mar 16, 2007
ReutersThe agency now anticipates completing its review by Aug. 19, the companies said. Frova won approval in 2001 for the acute treatment of migraine attacks,

FDA taking extra time to review Endo's migraine drug  -  Mar 16, 2007
The News Journal,The FDA is expected to complete its review of the companies' Supplemental New Drug Application for Frova by Aug. 19. The review was to have been completed

Endo Pharmaceuticals (ENDP) and Vernalis plc Announce Three-Month ...  -  Mar 16, 2007
StreetInsider.com (subscription),Supplemental New Drug Application (sNDA) for Frova 2.5 mg tablets for the expanded indication of short-term prevention of menstrual migraine (MM).

Market Report -- In Play (VNLS)  -  Mar 16, 2007
MSN MoneyVernalis and Endo announce three-month extension of PDUFA date for frova sNDA Endo Pharmaceuticals Holdings (ENDP) and VNLS announce that the FDA has

Vernalis annual losses widen  -  Mar 12, 2007
Hemscott,Separately, the group announced its partner, Menarini, has received pricing and reimbursement for migraine pill Frova in France. Following launch in France,

Chadds Ford drugmaker says FDA needs more time on migraine treatment  -  Mar 16, 2007
Therapeutics Daily (subscription) (press release),...require an additional three months to decide whether to approve the migraine drug Frova for prevention of headaches associated with menstrual periods.

Pre-Market Stock Notes (MAR 16, 2007)  -  Mar 16, 2007
24/7 Wall St.,...(ENDP) Endo Pharma and VNLS said the FDA will require an additional three months to review Endo's previously submitted Supplemental NDA for Frova 2.5MG

Vernalis says US FDA delays decision date for  -  Mar 16, 2007
Hemscott,Frova is already on sale as a pill to relieve pain after a migraine has started. Vernalis has asked for permission to market the drug as a prophylactic,

Event Brief of Q4 2006 Endo Pharmaceuticals Earnings Conference ...  -  Mar 1, 2007
Insurance News Net,Filed a supplemental NDA for Frova for the short-term prevention of menstrual migraine. 1. Has a 05/19/2007 PDUFA date. 6. Continued to advance the

EARNINGS WATCH Updates, advisories and surprises  -  Mar 12, 2007
MarketWatchThe company said that the Federal Drug Administration will respond to its application for approval of its Frova drug by May 19.

Results round-up: AT Communications, Aero, Bateman  -  Mar 12, 2007
ShareCast,...news flow in 2007 from four clinical programmes as well as increased revenues of its two marketed products, Apokyn and Frova,� said the group.

OUTLOOK - UK smaller companies results for the 2 weeks to March 23  -  Mar 9, 2007
Hemscott,The US OK of Frova for menstrual migraine is likely to be perceived as a significant catalyst in 2007, but Evolution believes prescriptions are unlikely to

Biotech In Review: Adams Respiratory Guides Lower  -  Mar 18, 2007
Seeking Alpha,Endo Pharma (ENDP) and Vernalis (VNLS) reported the FDA will take an additional 3 months to review the supplemental new drug application for Frova,

Charges Cause Profit Drop At Endo  -  Feb 23, 2007
Chester Daily Local Online,With Frova, the company is planning a pre-launch marketing program that would educate physicians on the different causes of migraines. At the time Frova

Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2006 ...  -  Feb 22, 2007
PharmaLive.com (press release),Frova(R). Net sales of Frova(R) were $11.5 million for the three months ended December 31, 2006 compared with $13.0 million in the same period in 2005.

Some facts about migraines  -  Feb 7, 2007
Pittsburgh Post Gazette,Other 5-HT agonists are almotriptan (Axert), naratriptan (Amerge), rizatriptan (Maxalt), zolmitriptan (Zomig), frovatriptan (Frova) and eletriptan (Relpax).

Vernalis Plc Announces Key Appointment in the US Commercial ...  -  Jan 16, 2007
PharmaLive.com (press release),Jean will lead the Medical Affairs function in the United States which promotes Apokyn(r) and co-promotes Frova(r) alongside its licensing partner,

Endo Pharmaceuticals Provides Financial Guidance for 2007  -  Jan 9, 2007
PharmaLive.com (press release),Endo's 2007 guidance does not reflect net sales from the expected second-half launch of Frova(R) for the anticipated expanded indication for prevention of

Endo's Plan to Bring In the Dough  -  Jan 10, 2007
MSNBCThe company hopes to gain an expanded marketing label on the migraine drug Frova, and it is preparing to file New Drug Applications in the first half of

Endo Guides FY07 EPS Below Consensus  -  Jan 8, 2007
Trading Markets,However, it does not reflect net sales from the expected second-half launch of Frova for the anticipated expanded indication for prevention of menstrual

Vernalis plc Initiates a Phase I Trial of a Promising New Approach ...  -  Dec 10, 2006
PR Newswire (press release),The company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders.

Endo Pharmaceuticals Appoints Charles Rowland as Chief Financial ...  -  Dec 6, 2006
PharmaLive.com (press release),Endo's commercial portfolio is focused primarily in pain management and includes nine branded products, led by Lidoderm(R), Opana(R), Opana(R) ER, Frova(R),

When A Winner Starts To Wane  -  Dec 6, 2006
BusinessWeekThe company is also counting on help from Frova, a pill for menstrual migraines that is expected to get broader FDA approval in mid-2007.

Endo Pharmaceuticals Reports Third Quarter 2006 Financial Results  Oct 24, 2006
Frova(R). Net sales of Frova(R) were $9.1 million and $29.1 million for the three and nine months ended September 30, 2006, respectively. ... -Drug Newswire (press release), Vernalis to Present at Cowen and Company 7th Annual Global Health ...  Nov 1, 2006
The company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. ... -Yahoo! News (press release) Endo Pharma Q3 EPS Dips Yet Tops Estimate; Reiterates FY06 ...  Oct 19, 2006
Net sales for Frova totaled $9.1 million for the three months period ended September 30, 2006, compared to $10.3 million in the year-ago quarter. ... -Trading Markets, Triptan-Experienced Migraine Patients Find Improved Management ...  Oct 11, 2006
...and have used medications in the triptan class experience better effectiveness and tolerability when they switch to frovatriptan (Frova), according to ... -DG News AstraZeneca, BAT, Glaxo, Shell: UK, Irish Equity Preview  Oct 25, 2006
Banking. ``We believe that expectations for its key migraine drug, Frova, are significantly too optimistic,'' the bank wrote in a note. ... -Bloomberg Publicado: Sab Oct 14, 2006 5:01 pm Asunto: Unless directed to do ...  Oct 14, 2006
...life. Always a step ahead of the other c freezone ildren his age, and always restless to do more, learn more, be frova more. With ... -Shell Security, Vernalis plc Initiates a Phase I Trial of a Promising New Approach ...  -  Dec 10, 2006
Yahoo! News (press release)The company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. ...

Endo Pharmaceuticals Appoints Charles Rowland as Chief Financial ...  -  Dec 6, 2006
Market Wire (press release)...company's 590-person sales force, where he will re-direct Endo's launch efforts on Opana® and Opana® ER, and prepare for the expected launch of Frova for the ...

When A Winner Starts To Wane  -  Dec 5, 2006
BusinessWeekThe company is also counting on help from Frova, a pill for menstrual migraines that is expected to get broader FDA approval in mid-2007. ...

Vernalis plc and Endo Pharmaceuticals Holdings Inc. Announce North ...  Aug 7, 2006
ENDP) (“Endo�), today announced an agreement for Vernalis to license exclusive North American sales and marketing rights to Frova™ (frovatriptan succinate ... -Biotechnology Investment Today

The New America  Aug 4, 2006
A few weeks ago, it and partner Vernalis (VNLS) asked the Food and Drug Administration to review Frova, a triptan drug, for a new condition. ... -Investor's Business Daily (subscription)

Pharmacy: Migraine medicine, antidepressants can mix to cause ...  Jul 30, 2006
...though, the FDA has issued a Public Health Advisory to warn physicians of the hazards of mixing migraine medicines such as Amerge, Axert, Frova, Imitrex, Maxalt ... -Houston Chronicle

Vernalis files menstrual migraine drug Frova with US regulators  Jul 20, 2006
LONDON (AFX) - Vernalis PLC said its drug for the short-term prevention of menstrual migraine, Frova, has been filed with US medicine regulators for marketing ... -Life Style Extra

Endo Pharmaceuticals Submits SNDA For Frova 2.5mg Tablets - Update  Jul 19, 2006
...(ENDP | charts | news | PowerRating) said that it has submitted a supplemental New Drug Application to the FDA for Frova 2.5 mg tablets for the short-term ... -Trading Markets

Vernalis Submits New Drug Application For Frova >VNLS  Jul 20, 2006
...announced that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova (frovatriptan succinate ... -Therapeutics Daily (subscription)

(PRN) - Husky Energy announces 2006 second quarter results ... [+]  Jul 19, 2006
...[+]. (PRN) - Endo Pharmaceuticals and Vernalis plc Announce the Filing of the Supplemental NDA for Frova(R) for Short-Term Prevention of Menstrual Migraine ... ... -Bolsamania.com

Stocks to Watch, July 20: Apple and Intel  Jul 19, 2006
Endo Pharmaceuticals Holdings Inc. (ENDP) said it has submitted a supplemental new drug application to the Food and Drug Administration for Frova for the short ... -FOX News

Stocks to Watch: Apple, Intel, Microsoft, United Health, Wal-Mart ...  Jul 20, 2006
Endo Pharmaceuticals Holdings (ENDP) said it has submitted a supplemental new drug application to the Food and Drug Administration for Frova for the short-term ... -Minyanville.com

Rotary club decides on its new leadership  Jul 14, 2006
The newly elected officers are Gary Whitney, president; Barbara Frova, vice president and immediate past president; Jeremy Brewer, secretary; and Hal Ward ... -Simi Valley Acorn

FDA approves Endo drugs  Jun 23, 2006
220 sales representatives to promote all formulations of Opana as well as its existing portfolio of branded pain relief products, including Lidoderm and Frova. ... -Bizjournals.com

Endo Receives FDA Approval for Opana(R) ER (oxymorphone HCl) ...  Jun 23, 2006
...representatives to promote all formulations of Opana(R) as well as its existing portfolio of branded products, including Lidoderm(R) and Frova(R). Additionally ... -MSN Money

Endo Receives FDA Approval for Opana(R) ER (oxymorphone HCl) ...  Jun 23, 2006
220 sales representatives to promote all formulations of Opana® as well as its existing portfolio of branded products, including Lidoderm® and Frova®. ... -Yahoo! News

Terry Marvin named Simi Rotarian of the Year  Jun 29, 2006
...the Rotary motto of ¿Service Above Self" through her tireless dedication to our club and projects in our community," said Barbara Frova, outgoing president of ... -Ventura County Star (subscription)



Cytomyx breaks mould  Mar 21, 2006
Vernalis reported a full year pre-tax loss of £34.4m up from £27.4m in 2004 but said it could be cash generative within two years if Frova, its treatment for ... - Cambridge Evening News

Politicians should think outside of the wedlock box  Apr 2, 2006
...large. I immediately thought of entrepreneur Barbara Frova as a possible woman of the year. She was, after all, the woman of a month. ... - Ventura County Star (subscription)

Vernalis Achieves Primary End Point in Phase IIa Trial of V1003  Mar 16, 2006
The Company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. ... - PharmaLive.com

Pa. drugmaker aggressively diversifies  Feb 7, 2006
The company also expects to file a supplemental application for Frova, a drug to treat acute migraine headaches it licenses from Vernalis Plc. ... - The News Journal,

Updates, advisories and surprises  Feb 15, 2006
...more than doubled to $72.9 million, or 54 cents a share, with revenue climbing 53% to $241 million on sales of drugs including Lidoderm, Percocet and Frova. ... - Investor's Business Daily (subscription)

Pa. drugmaker aggressively diversifies  Feb 7, 2006
The company also expects to file a supplemental application for Frova, a drug to treat acute migraine headaches it licenses from Vernalis Plc. ... - The News Journal

Vernalis PLC Launch of US Sales Force  Jan 24, 2006
This 34 strong team is marketing Vernalis' Parkinson's disease drug Apokyn(R), as well as co-marketing the company's migraine drug, Frova(R), alongside Endo ... - PharmaLive.com

Vernalis starts selling Parkinson's drug Apokyn in US  Jan 24, 2006
PLC said its 34-strong specialty neurology US sales force has started to market its Parkinson's disease drug Apokyn and migraine drug Frova, alongside Endo ... - Forbes

Elan meldt financiële resultaten vierde kwartaal en hele jaar ...  Jan 31, 2006
...manufacturing business in Italy, the pain portfolio of products, Actiq(TM), the dermatology portfolio of products, Abelcet(TM) US and Canada, Frova(TM), Myobloc ... - Netherlands Corporate News (persbericht)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional